Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts At Tertiary Care Hospital in Karachi.

February 6, 2025 updated by: Rashida Kaizar, Jinnah Postgraduate Medical Centre

Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts.

Identify the effects of combined intralesional furosemide 20mg/2ml and digoxin 0.5mg/2ml in cutaneous warts given weekly are rather safe and effective treatment for cutaneous warts, focusing on their effectiveness and safety, at a tertiary care hospital in Karachi, Pakistan.

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Detailed Description

Cutaneous warts are benign growth caused by human papilloma virus. Virus have more than 100 types of which few are responsible for cutaneous disease. Both injection furosemide and digoxin cause decrease intracellular potassium levels by interacting with cell membrane ion co-transporters (Na+/K+-ATPase and Na+-K+-2Cl-co-transporter-1) thereby causing delay in viral replication. The purpose of study is to evaluate the effects of both furosemide and digoxin given 0.2 ml once weekly for five weeks on viral warts.

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Sindh
      • Karachi, Sindh, Pakistan, 75500
        • Jinnah Postgraduate Medical Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Patients presenting with greater than or equal to two warts
  2. Either gender.
  3. Age 18 - 60 years. -

Exclusion Criteria:

  1. Pregnant or lactating women.
  2. Patient not giving informed consent.
  3. Patient received any treatment in the last 3 months period.
  4. Patient with acute illness and immuno-suppressive disease.
  5. Patient taking immuno-suppressive drugs.
  6. Patient having hypersensitivity to any investigational medicine.
  7. Patient having cutaneous warts on face and genitals.
  8. Patient having cardiovascular disease.
  9. Patient having renal disease. -

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Patients
Patients with age between 18-60 years having more than two cutaneous warts will be given combined intralesional furosemide (20mg/2ml) and digoxin (0.5mg/2ml) 0.2 ml at the base of warts once weekly for five weeks
Drug: Furosemide
Furosemide 20mg/2ml and digoxin 0.5mg/2ml given 0.2 ml into the wart base once weekly for 5 weeks
Other Names:
  • Digoxin

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Size of cutaneous wart
Time Frame: 5 weeks
Change in the dimensions of cutaneous wart assessed by Physician's wart assessment scale weekly and through photographs taking at the start and end of the study.
5 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Jinnah Postgraduate Medical Centre

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2025

Primary Completion (Estimated)

August 30, 2025

Study Completion (Estimated)

September 30, 2025

Study Registration Dates

First Submitted

February 6, 2025

First Submitted That Met QC Criteria

February 6, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 6, 2025

Last Verified

November 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NO.F.2-81/2024-GENL/22/JPMC

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe